Switching from biosimilar adalimumab to originator adalimumab and vice versa as an alternative to target switch in patients with hidradenitis suppurativa: a single center experience

被引：0
|
作者：
Roldan, Fernando Alfageme [1 ]
Cembrero, Hirune [1 ]
Salguero, Irene [1 ]
Martinez, Constanza [1 ]
Roustan, Gaston [1 ]
机构：
[1] Hosp Univ Puerta de Hierro Majadahonda, Dermatol, Madrid, Spain
来源：
EXPERIMENTAL DERMATOLOGY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P167
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [1] Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
    Montero-Vilchez, Trinidad
    Cuenca-Barrales, Carlos
    Rodriguez-Tejero, Andrea
    Martinez-Lopez, Antonio
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [2] Switching from adalimumab originator to biosimilar: clinical experience in hidradenitis suppurativa patients
    Montero-Vilchez, Trinidad
    Rodriguez-Tejero, Andrea
    Sanchez-Diaz, Manuel
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 80 - 80
  • [3] Drug survival of adalimumab biosimilar and adalimumab originator in patients with hidradenitis suppurativa : A retrospective single centre cohort of 80 patients
    Alfageme, Fernando
    Grau, Merce
    Hospital, Mercedes
    Salguero, Irene
    Aguilar, Laura
    Roustan, Gaston
    EXPERIMENTAL DERMATOLOGY, 2022, 31 : 63 - 64
  • [4] Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa
    Ricceri, Federica
    Rosi, Elia
    Di Cesare, Antonella
    Pescitelli, Leonardo
    Fastame, Maria Thais
    Prignano, Francesca
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [5] Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
    Burlando, Martina
    Fabbrocini, Gabriella
    Marasca, Claudio
    Dapavo, Paolo
    Chiricozzi, Andrea
    Malvaso, Dalma
    Dini, Valentina
    Campanati, Anna
    Offidani, Annamaria
    Dattola, Annunziata
    Caro, Raffaele Dante Caposiena
    Bianchi, Luca
    Venturini, Marina
    Gisondi, Paolo
    Guarneri, Claudio
    Malara, Giovanna
    Trifiro, Caterina
    Malagoli, Piergiorigio
    Fargnoli, Maria Concetta
    Piaserico, Stefano
    Carmisciano, Luca
    Castelli, Riccardo
    Parodi, Aurora
    BIOMEDICINES, 2022, 10 (10)
  • [6] Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response: Data from the German HS registry HSBEST
    Ohm, Frenz
    Kirsten, Natalia
    Gehrdau, Kathrin
    Stephan, Brigitte
    Ben-Anaya, Nesrine
    Pinter, Andreas
    Bechara, Falk G.
    Presser, Dagmar
    Zouboulis, Christos C.
    Augustin, Matthias
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 24 - 25
  • [7] Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest
    Kirsten, Natalia
    Ohm, Frenz
    Gehrdau, Kathrin
    Girbig, Gefion
    Stephan, Brigitte
    Ben-Anaya, Nesrine
    Pinter, Andreas
    Bechara, Falk G.
    Presser, Dagmar
    Zouboulis, Christos C.
    Augustin, Matthias
    LIFE-BASEL, 2022, 12 (10):
  • [8] Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study
    Grau-Perez, Merce
    Rodriguez-Aguilar, Laura
    Roustan, Gaston
    Alfageme, Fernando
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (05) : E678 - E680
  • [9] Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
    Nielsen, Valdemar Wendelboe
    Lund, Tamara Theresia
    Gniadecki, Robert
    Olsen, Rasmus Huan
    Nissen, Christoffer Valdemar
    Schwensen, Jakob Ferlov Baselius
    Thomsen, Simon Francis
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [10] Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
    Jose Casanova, Maria
    Nantes, Oscar
    Varela, Pilar
    Vela-Gonzalez, Milagros
    Rivero, Montserrat
    Sierra-Gabarda, Olivia
    Riestra, Sabino
    Barreiro-de Acosta, Manuel
    del Mar Martin-Rodriguez, Maria
    Jerusalen Gargallo-Puyuelo, Carla
    Reygosa, Cristina
    Munoz, Roser
    Garcia de la Filia-Molina, Irene
    Nunez-Ortiz, Andrea
    Kolle, Lilyan
    Calafat, Margalida
    Maria Huguet, Jose
    Iglesias-Flores, Eva
    de Jesus Martinez-Perez, Teresa
    Bosch, Orencio
    Maria Duque-Alcorta, Jose
    Frago-Larramona, Santiago
    Van Domselaar, Manuel
    Manuel Gonzalez-Cosano, Victor
    Bujanda, Luis
    Rubio, Saioa
    Mancebo, Alejo
    Castro, Beatriz
    Garcia-Lopez, Santiago
    de Francisco, Ruth
    Nieto-Garcia, Laura
    Laredo, Viviana
    Gutierrez-Casbas, Ana
    Mesonero, Francisco
    Leo-Carnerero, Eduardo
    Canete, Fiorella
    Ruiz, Lucia
    Gros, Beatriz
    del Moral-Martinez, Maria
    Rodriguez, Cristina
    Chaparro, Maria
    Gisbert, Javier P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (01) : 60 - 70
12345